A hydroxyl radical reactive non-natural amino acid and its preparation method and application
By developing fluorescent probes constructed by non-natural amino acid HBCF and genetic codon expansion technology, the challenge of intracellular OH detection is solved, and the selective fluorescence detection of OH is realized, providing high selectivity and high sensitivity detection methods. .
Patent Information
- Application Number
- CN202410345094.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-25
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-03-25
AI Technical Summary
The prior art is difficult to detect the generation, distribution and dynamic fluctuations of hydroxyl radicals (·OH) in cells in real time and selectively, especially due to its high reactivity, short lifetime and low concentration, resulting in real-time detection of endogenous ·OH. Challenging.
A non-natural amino acid HBCF was developed to construct a genetically encoded fluorescent probe with chemical reaction activity using its chemical reaction with OH. The HBCF was inserted into the key sites of the circular arrangement of superfolded green fluorescent protein through genetic codon expansion technology. After reacting DHBC side chain with ·OH, tyrosine analogs are generated, which significantly enhances the fluorescence signal and achieves fluorescence detection of ·OH.
Selective fluorescence detection of ·OH in vitro was realized. The response time, sensitivity and selectivity of the probe were verified through fluorescence spectroscopy and mass spectrometry analysis, and proved that HBCF was caused by reacting with ·OH to generate tyrosine analog AF. Fluorescence enhancement provides a high selectivity and high sensitivity·OH detection method.
Smart Images

Figure BDA0004758018170000011 
Figure BDA0004758018170000071 
Figure BDA0004758018170000072
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biological sample detection, and in particular to the field of ·OH detection in biological samples. Technical Background
[0002] Reactive oxygen species (ROS) play an important regulatory role in many physiological and pathological processes. Existing studies have shown that cellular oxidative stress is caused by an imbalance between the production and elimination of reactive oxygen species in cells. ·OH (hydroxyl radical) is the most reactive intracellular ROS. When its concentration increases abnormally, it will attack biological macromolecules in the body, causing serious cell damage, and then induce a variety of diseases, including stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis and cardiovascular disease. Therefore, a highly selective and sensitive method is needed to detect the generation, distribution and dynamic fluctuations of ·OH in living systems in real time to fully understand its biological effects. However, due to the high reactivity, short life span and low concentration of endogenous ·OH in cells, the real-time detection of endogenous ·OH is extremely challenging. With the development of genetic codon expansion technology, scientists have developed a series of unnatural amino acids (UAA) that can react with biologically active species for the construction of genetically encoded fluorescent probes based on chemical reactivity, and have successfully achieved ONOO - Detection and imaging.
[0003] In 2020, Liu Zhibo's research group at Peking University developed a fluorescent probe DHBC-MeRho with 3,5-dihydroxybenzyl carbamate (DHBC) as a masking group. Its DHBC group can be selectively removed by ·OH produced by nuclear radiation, thereby reacting rapidly and releasing fluorescence.
[0004] Based on this, the present invention intends to combine the chemical reaction of DHBC group and ·OH with genetic codon expansion technology to develop and synthesize the ·OH-reactive unnatural amino acid HBCF for the preparation of chemically reactive genetically encoded ·OH probes. Summary of the invention
[0005] The object of the present invention is to provide an OH-reactive non-natural amino acid HBCF (tyrosine derivative) and a method for constructing a chemically reactive genetically encoded OH probe using the same. Figure 1As shown, the present invention designs and synthesizes a tyrosine derivative 4-(3,5-dihydroxybenzyloxycarbonylamino)-L-phenylalanine (HBCF) containing a DHBC side chain. The DHBC side chain group can react selectively with ·OH to generate the tyrosine analog 4-amino-L-phenylalanine (AF) in situ after ortho-hydroxylation, 1,4- or 1,6-elimination. The present invention further utilizes genetic codon expansion technology to site-specifically insert HBCF into the key site of the circularly permutated superfolded green fluorescent protein (cpsfGFP) chromophore, and constructs a genetically encoded ·OH fluorescent probe. Figure 2 As shown, before the reaction with ·OH, the cpsfGFP introduced into HBCF had almost no fluorescence because the key site of the chromophore was masked by the side chain of HBCF. After the reaction with ·OH, the DHBC group of HBCF was cut off to generate the tyrosine analog AF, which significantly enhanced the fluorescence of cpsfGFP, thereby realizing the fluorescence detection of ·OH.
[0006] To achieve the above object, the present invention provides the following technical solutions:
[0007] The present invention provides a class of non-natural amino acid lysine analogs that can react with ·OH, and its structural formula is as follows:
[0008]
[0009] The invention is characterized in that it contains catechol and 4-amino-L-phenylalanine structures.
[0010] Specifically, this type of non-natural amino acid is a type of tyrosine derivative containing a DHBC side chain, 4-(3,5-dihydroxybenzyloxycarbonylamino)-L-phenylalanine (HBCF), whose DHBC side chain group can selectively react with ·OH to generate a tyrosine analog 4-amino-L-phenylalanine (AF) in situ after ortho-hydroxylation, 1,4- or 1,6-elimination.
[0011] The present invention also provides a chemical synthesis method of non-natural amino acid HBCF, comprising the following steps:
[0012] Step 1) firstly protecting the carboxylic acid group of compound 1 (Nα-tert-butyloxycarbonyl-4-amino-L-phenylalanine) with methyl ester to obtain compound 2;
[0013] Step 2) Compound 3 (methyl 3,5-dihydroxybenzoate) is treated with tert-butyldimethylsilyl chloride to protect the hydroxyl group to obtain compound 4;
[0014] Step 3) Compound 4 is reduced with lithium aluminum hydride to obtain compound 5;
[0015] Step 4) protecting the amino group of compound 4 with a tert-butyloxycarbonyl group to obtain compound 5;
[0016] Step 5) Compound 5 reacts with triphosgene and then reacts with compound 2 to generate compound 6;
[0017] Step 6) After deprotection with tetrabutylammonium fluoride, lithium hydroxide and trifluoroacetic acid, a hydroxyl radical-reactive unnatural amino acid HBCF is obtained.
[0018] The present invention also provides a compound connected with any of the above-mentioned non-natural amino acids.
[0019] The present invention also provides a composition comprising any of the above-mentioned non-natural amino acids.
[0020] The present invention also provides an expression system or translation system comprising any of the above-mentioned unnatural amino acids.
[0021] The use of a class of hydroxyl radical reactive non-natural amino acids described in the present invention in constructing hydroxyl radical reactive fluorescent probes;
[0022] The hydroxyl radical reactive fluorescent probe of the present invention is a probe that introduces any of the above-mentioned non-natural amino acids into a specific site of a biological macromolecule; preferably, the probe is a genetically encoded fluorescent protein probe of cpsfGFP-Y163HBCF.
[0023] The hydroxyl radical reactive fluorescent probe of the present invention comprises a combination of any of the above hydroxyl radical reactive fluorescent probes.
[0024] The hydroxyl radical reactive fluorescent probe of the present invention comprises any one of the above-mentioned hydroxyl radical reactive fluorescent probe expression systems or translation systems.
[0025] The use of any of the hydroxyl radical reactive fluorescent probes described in the present invention, or the composition described therein, or the expression system or translation system described therein, in imaging or detecting hydroxyl radical reactivity in a sample.
[0026] Compared with the prior art, the present invention has the following beneficial effects:
[0027] 1) The present invention utilizes genetic codon expansion technology to develop a new ·OH-reactive UAA based on a tyrosine analog and an ·OH-reactive group, namely HBCF, and thereby develops a new genetically encoded ·OH fluorescent probe cpsfGFP-Y163HBCF, which can selectively detect ·OH by fluorescence in vitro;
[0028] 2) The present invention synthesized the non-natural amino acid HBCF based on the ·OH reactive group DHBC and 4-amino-phenylalanine AF, and verified by LC-MS that HBCF can react with ·OH to generate AF. The present invention screened a series of MmPylRS mutants, obtained a synthetase mutant (HBCF-RS) that can effectively recognize HBCF, and achieved site-specific insertion of HBCF into the target protein in the prokaryotic system Escherichia coli;
[0029] 3) The present invention utilizes genetic codon expansion technology to site-specifically introduce HBCF into the key tyrosine site of fluorescent protein, and recombinantly expresses and purifies the fluorescent probe cpsfGFP-Y163HBCF in Escherichia coli. The response time, sensitivity and selectivity of the probe for detecting ·OH in vitro are systematically characterized by fluorescence spectral analysis and fluorescence intensity quantification. Mass spectrometry analysis and negative control experiments further demonstrate that the HBCF on the probe causes fluorescence enhancement by reacting with ·OH to generate the tyrosine analog AF. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 :The structure of HBCF and its selective reaction with ·OH;
[0031] Figure 2 :Synthesis route of HBCF;
[0032] Figure 3 :Reaction of Boc-HBCF and ·OH;
[0033] Figure 4 : LC-MS results after the reaction of Boc-HBCF with ·OH;
[0034] Figure 5 :Results of screening for synthase mutants that identify HBCF;
[0035] Figure 6: Results of site-directed insertion analysis of HBCF in E. coli: (A) Western blot analysis comparing the site-directed insertion efficiency of two synthases into HBCF, the concentration of HBCF was 1mM; (B) Chemical structure of BocK; (C) Western blot analysis comparing the protein expression of sfGFP-N150BocK and sfGFP-N150HBCF, the concentration of BocK was 1mM, the concentration of HBCF was 2mM; (D) Western blot analysis and (E) fluorescence intensity analysis of the expression of sfGFP-N150HBCF protein under different concentrations of HBCF. CB: Coomassie Brilliant Blue staining.
[0036] Figure 7 : Purification and characterization of sfGFP-N150HBCF protein in E. coli: (A) SDS-PAGE electrophoresis of purified sfGFP-N150HBCF protein; (B) ESI-MS mass spectrometry analysis of sfGFP-N150HBCF protein, the mass spectrum was deconvoluted using BioPharma Finder. CB: Coomassie Brilliant Blue staining.
[0037] Figure 8 : Expression of several fluorescent proteins inserted into HBCF in E. coli: (A) Immunoblotting analysis of the expression of EGFP-Y66TAG, sfGFP-Y66TAG, cpsfGFP-Y163TAG and mCherry-Y72TAG inserted into HBCF, the concentration of HBCF was 2mM; (B) Immunoblotting analysis of the expression of cpsfGFP-Y163TAG protein under different concentrations of HBCF. CB: Coomassie Brilliant Blue staining.
[0038] Fig. 9 : SDS-PAGE and mass spectrometry analysis of cpsfGFP-Y163HBCF probe: (A) SDS-PAGE electrophoresis of purified cpsfGFP-Y163HBCF protein; (B) ESI-MS mass spectrometry analysis of cpsfGFP-Y163HBCF protein, mass spectrometry was deconvoluted using BioPharma Finder. CB: Coomassie Brilliant Blue staining; "-Met" indicates that the initiating methionine at the N-terminus was removed by methionine aminopeptidase in Escherichia coli.
[0039] Fig.10 :The fluorescence response of cpsfGFP-Y163HBCF probe to ·OH in vitro;
[0040] Fig.11:Characterization of cpsfGFP-Y163HBCF probe for in vitro detection of ·OH. (A) Linear relationship between the fluorescence intensity of 0.5μM probe at 510nm and ·OH concentration (t=60min); (B) Fluorescence response of 0.5μM probe to low concentration of ·OH at 510nm (t=60min), statistical analysis was performed using one-way ANOVA, **p<0.01; (C) Fluorescence response kinetics of 0.5μM probe to ·OH (4μM);
[0041] Fig.12 :The selectivity of cpsfGFP-Y163HBCF probe for detecting ·OH in vitro;
[0042] Fig.13 : ESI-MS mass spectrum analysis of cpsfGFP-Y163HBCF after reaction with ·OH;
[0043] Fig.14 :Synthesis route of unnatural amino acid BCF;
[0044] Fig.15 : Screening diagram of synthase mutants identifying BCF;
[0045] Fig.16 :Analysis of protein inserted into BCF in E. coli: (A) Immunoblotting analysis to compare the protein expression of sfGFP-N150BocK and sfGFP-N150BCF, the concentration of BocK was 1mM, the concentration of BCF was 0.5mM; (B) Immunoblotting analysis of the protein expression of sfGFP-N150BCF under different concentrations of BCF. CB: Coomassie Brilliant Blue staining.
[0046] Fig.17 :SDS-PAGE and mass spectrometry analysis of cpsfGFP-Y163BCF protein. (A) SDS-PAGE electrophoresis of purified cpsfGFP-Y163BCF protein; (B) ESI-MS mass spectrometry analysis of cpsfGFP-Y163BCF protein;
[0047] Fig.18 : Fluorescence response of negative control cpsfGFP-Y163BCF to ·OH in vitro. (A) Fluorescence response of 0.5μM cpsfGFP-Y163HBCF probe and negative control cpsfGFP-Y163BCF to different concentrations of ·OH, with excitation wavelength of 470nm and emission wavelength of 510nm; (B) Fluorescence response spectrum of 0.5μM negative control cpsfGFP-Y163BCF to different concentrations of ·OH, with excitation wavelength of 470nm. The incubation time was 60min, and the data were shown as mean ± standard deviation (n = 3).
[0048] The embodiments of the present invention will be described in detail below in conjunction with the examples, but it will be appreciated by those skilled in the art that the following examples are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. If no specific conditions are specified in the examples, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased from the market.
[0049] Definition of some terms
[0050] Unless otherwise defined hereinafter, the meaning of all technical terms and scientific terms used in the specific embodiments of the present invention are intended to be the same as those generally understood by those skilled in the art. Although it is believed that the following terms are well understood by those skilled in the art, the following definitions are still set forth to better explain the present invention.
[0051] As used in the present invention, the terms "comprise", "comprising", "having", "containing" or "involving" are inclusive or open-ended, and do not exclude other unrecited elements or method steps. The term "consisting of" is considered to be a preferred embodiment of the term "comprising". If a group is defined below as comprising at least a certain number of embodiments, this should also be understood to disclose a group that preferably consists of only these embodiments.
[0052] When referring to a singular noun an indefinite or definite article e.g. "a" or "an", "the" or "an" is used, this includes a plural of that noun.
[0053] The term "approximately" in the present invention indicates an accuracy range that can be understood by those skilled in the art and still ensures the technical effect of the characteristic in question. The term generally indicates ±10%, preferably ±5%, of the indicated value.
[0054] In addition, the terms first, second, third, (a), (b), (c), and the like in the specification and claims are used to distinguish similar elements and are not necessarily required to describe a sequential or chronological order. It should be understood that the terms so used are interchangeable under appropriate circumstances, and that the embodiments described in the present invention can be implemented in other sequences than those described or illustrated in the present invention.
[0055] The following terms or definitions are provided merely to aid understanding of the present invention. These definitions should not be construed as having a scope less than that understood by those skilled in the art.
[0056] The term "·OH reactivity" used in the present invention means: having the property of reacting specifically with ·OH. Reaction is also a chemical term, which means the process of generating new chemical substances by the interaction between two or more chemical substances, i.e. chemical reaction.
[0057] The term "associated" as used herein refers to components that function together, such as an orthogonal tRNA and an orthogonal aminoacyl-tRNA synthetase. These components may also be referred to as being "complementary" to each other.
[0058] The term "homologous" as used in the present invention means: In genetics, the concept of homology mainly refers to sequence homology, indicating that two or more protein or DNA sequences have the same ancestor. Homologous sequences are also likely to have similar functions. Two sequences are either homologous or not, and there is no such concept as "homology". The homologous parts of the sequence are also called conserved.
[0059] The term "cognate tRNA" as used in the present invention refers to a cognate tRNA that is homologous and functions with a translation system of interest. It should be understood that it is preferred to utilize the cognate tRNA of the present invention in conjunction with a translation system to react to a selector codon during translation and that essentially any amino acid (whether natural or non-natural) can be incorporated into an extending polypeptide.
[0060] The term "pyrrolysyl-tRNA synthetase" used in the present invention refers to an enzyme that catalyzes the activation of pyrrolysine and covalently binds to the 3' end of the corresponding tRNA molecule. Pyrrolysine (Pyl) is found in the methylamine methyltransferase of methanogens and is the 22nd amino acid known to participate in protein biosynthesis. Unlike standard amino acids, pyrrolysine (Pyl) is formed by the sense coding of the stop codon UAG. Correspondingly, methanogens also contain specific pyrrolysyl-tRNA synthetases (PylRS) and pyrrolysine tRNA (tRNA Pyl ), which has a special structure different from classical tRNA. Methanogens generate pyrrolysyl-tRNA through direct and indirect pathways Pyl (Pyl-tRNA Pyl), which may control the coding of UAG to become a stop codon or pyrrolysine through a special structure on mRNA or other mechanisms that have not yet been discovered. Wild-type pyrrolysyl-tRNA synthetase (PylRS) can be obtained from, for example, Methanosarcinamazei, Methanosarcinabarkeri, and Methanosarcina acetivorans, which are methanogenic archaea, but are not limited to these.
[0061] The term "aminoacyl-tRNA synthetase" used in the present invention refers to: based on the wild-type pyrrolysyl-tRNA synthetase (PylRS), it is prepared by introducing mutations by various methods. The types of lysine derivatives that can be activated by the wild-type PylRS are limited. For example, the pyrrolysyl-tRNA synthetase mutant HBCFRS in the present invention belongs to a "mutant pyrrolysyl-tRNA synthetase". Through the mutant PylRS (aRS, bRS) of the present invention, even for the unnatural amino acid HBCF that is inactive when the wild-type PylRS is used, it can be efficiently introduced into the protein.
[0062] The term "unnatural amino acid" used in the present invention refers to any amino acid, modified amino acid and / or amino acid analog that is not among the 20 common natural amino acids. For example, the present invention can use the unnatural amino acid HBCF.
[0063] The term "affinity purification" used in the present invention refers to a method of purifying proteins, which utilizes the principle of specific binding between biological molecules to separate and purify biological substances.
[0064] The term "translation system" as used herein refers to the components that incorporate amino acids into an extending polypeptide chain (protein). The components of a translation system may include, for example, ribosomes, tRNAs, synthetases, mRNAs, etc. The O-tRNAs and / or O-RSs of the present invention may be added to or part of an in vitro or in vivo translation system, for example, in non-eukaryotic cells, such as bacteria (e.g., E. coli), or in eukaryotic cells, such as yeast, mammalian cells, plant cells, algae cells, fungal cells, insect cells, etc.
[0065] The term "PBS" used in the present invention refers to phosphate buffered saline, which is well known and widely used by those skilled in the art.
[0066] The present invention is further described by the accompanying drawings and the following examples, which are only for illustrating specific embodiments of the present invention and should not be construed as limiting the scope of the present invention in any way. DETAILED DESCRIPTION
[0067] Example 1 Design and preparation of OH (hydroxyl radical) reactive unnatural amino acid HBCF
[0068] The synthetic route of HBCF is as follows Figure 2 As shown. The present invention studies the synthesis of HBCF using commercially available Nα-tert-butyloxycarbonyl-4-amino-L-phenylalanine (Nα-Boc-4-amino-L-phenylalanine, Boc-AF, compound 1) and 3,5-dihydroxybenzoic acid methyl ester (3,5-Dihydroxy-2-methylbenzoate, compound 3) as starting materials. In order to improve the yield, the carboxylic acid group of compound 1 is first protected with methyl ester to obtain compound 2. Compound 3 is protected with tert-butyldimethylsilyl chloride to obtain compound 4. Compound 4 is reduced with lithium aluminum hydride to obtain compound 5, which is then reacted with triphosgene and then with compound 2 to generate compound 6. Compound 6 is sequentially deprotected with tetrabutylammonium fluoride, lithium hydroxide and trifluoroacetic acid to obtain the non-natural amino acid HBCF.
[0069] The specific preparation steps of HBCF are as follows (see Figure 2 ):
[0070] Compound 2 synthesis.
[0071] Compound 1 (1.85 g, 6.59 mmol) was dissolved in methanol (40 mL) and cooled to 0°C, and thionyl chloride (785 mg, 6.59 mmol) was slowly added dropwise. The reaction solution was slowly restored to room temperature and stirred for 2.5 hours. After the reaction was completed, most of the methanol was removed by vacuum pump decompression concentration, and then dissolved in ethyl acetate and washed with saturated sodium bicarbonate and brine. Finally, it was dried over anhydrous sodium sulfate solid and filtered, and the filtrate was concentrated by vacuum pump decompression to obtain yellow oily liquid compound 2-2 (1.92 g, 96%). 1HNMR (300MHz, CDCl3) δ6.89 (d, J = 8.3Hz, 2H), 6.61 (d, J = 8.4Hz, 2H), 4.95 (d, J = 7.7H z,1H),4.50(dd,J=13.7,5.9Hz,1H),3.70(s,3H),2.99–2.95(m,2H),1.41(s,9H).13C NMR (75MHz, CDCl3) δ172.70,155.28,145.45,130.25,125.75,115.41,79.94,54.70,52.25,37.56,28.42.HRMS calcd for C15H22N2O4[M+H]+:295.1658; found:295.1650.
[0072] Compound 4 synthesis.
[0073] Compound 3 (1 g, 5.95 mmol) was dissolved in DCM (40 mL), and then triethylamine (1.44 g, 14.27 mmol), 4-dimethylaminopyridine (363 mg, 2.97 mmol) and tert-butyldimethylsilyl chloride (1.97 g, 13.08 mmol) were added in sequence, and stirred at room temperature for 12 hours. After the reaction was completed, the mixture was quenched with saturated ammonium chloride solution and extracted with DCM (3×18 mL). The organic phase was washed, dried, and purified to obtain a colorless liquid compound 2-4 (2.17 g, 92%). 1 HNMR(300MHz, CDCl3)δ7.12(d,J=2.3Hz,2H),6.52(t,J=2.3Hz,1H),3.87(s,3H),0.98(s,18H),0.20(s,12H).13C NMR(75MHz, CDCl3)δ166.89,156.64,131.95,116.93,114.69,52.24,25.76,18.31.HRMScalcd for C20H36O4Si2[M+H]+:397.2230; found:397.2224.
[0074] Compound 5 synthesis.
[0075] Compound 4 (2.17 g, 5.49 mmol) was dissolved in THF (50 mL), and lithium aluminum tetrahydride (313 mg, 8.24 mmol) was added in portions, and stirred at room temperature overnight. After the reaction was completed, water was added to quench at 0°C. After filtration and concentration, 100 mL of ethyl acetate was added for extraction, and the organic phase was washed, dried, and purified to obtain a colorless liquid compound 5 (1.31 g, 65%). 1 HNMR(300MHz, CDCl3)δ6.46(d,J=2.1Hz,2H),6.26(s,1H),4.53(s,2H),2.26(s,1H),0.98(s,18H),0.19(s,12H).13C NMR(75MHz, CDCl3)δ156.74,143.26,111.86,111.21,65.03,25.78,18.29.HRMS calcd for C19H36O3Si2[M+H]+:369.2281; found:369.2275.
[0076] Compound 6 synthesis.
[0077] Compound 5 (1 g, 2.72 mmol) was dissolved in DCM (40 mL), triphosgene (322 mg, 1.09 mmol) was added, and the mixture was stirred overnight at room temperature. After concentration under reduced pressure, the mixture was directly put into the next step. Compound 2-2 (382 mg, 1.30 mmol) was dissolved in DCM (20 mL), triethylamine (390 mg, 3.89 mmol), 4-dimethylaminopyridine (16 mg, 0.13 mmol) and the product of the reaction of 5 with triphosgene (1.12 g) were added in sequence, and the mixture was reacted at room temperature for 3 hours. After the reaction was completed, the mixture was quenched with saturated ammonium chloride solution and extracted with DCM (3×10 mL). The organic phase was washed, dried and purified to obtain white solid compound 2-6 (714 mg, 80%). 1H NMR (300MHz, CDCl3) δ7.31(d,J=8.0Hz,2H),7.05(d,J=8.2Hz,2H),6.74(s,1H),6.48(s,2H),6.29(s,1H),5.05(s,2H),4 .98(d,J=7.7Hz,1H),4.54(d,J=7.2Hz,1H),3.70(s,3H),3.10–2.95(m,2H),1.41(s,9H),0.97(s,18H),0.19(s,12H).13C NMR (75MHz, CDCl3) δ172.44,156.81,155.22,153.36,138.02,136.92,131.14,130.04,118.9 5,113.22,111.91,80.09,66.85,54.55,52.35,37.76,29.83,28.42,25.79,18.32.HRMScalcd forC35H56N2O8Si2[M+Na]+:711.3473; found:711.3469.
[0078] Compound 7 synthesis.
[0079] Compound 6 (270 mg, 0.39 mmol) was dissolved in THF (10 mL), and tetrabutylammonium fluoride (1.18 mL, 1.18 mmol) was added, and the mixture was reacted at room temperature for 2 hours. After the reaction, the mixture was concentrated under reduced pressure to remove most of the THF, and then dissolved in ethyl acetate (50 mL) and washed with a saturated sodium bicarbonate solution. After drying and purification, a light yellow solid compound 7 (140 mg, 78%) was obtained. 1HNMR(500MHz,d6-DMSO)δ9.67(s,1H),9.28(s,2H),7.37(d,J=8.2Hz,2H),7.24(d,J=8.0Hz,1H),7.13(d,J=8.5Hz,2H),6.2 4(d,J=2.2Hz,2H),6.15(t,J=2.2Hz,1H),4.95(s,2H),4.14–4.09(m,1H),3.60(s,3H),2.93–2.76(m,2H),1.32(s,9H).13C NMR(126MHz,d6-DMSO)δ173.12,158.95,155.90,153.91,139.17,138.05,131.96 ,129.88,118.57,106.18,102.49,78.82,66.05,55.84,52.24,36.36,28.63.HRMS calcd for C23H28N2O8[M+Na]+:483.1743; found:483.1739.
[0080] Synthesis of compound Boc-HBCF:
[0081]
[0082] Compound 7 (110 mg, 0.24 mmol) was dissolved in a mixed solution of 1 mL methanol and 1 mL tetrahydrofuran, and then a solution of lithium hydroxide (1.2 mg, 4.78 mmol) in water (1 mL) was added and reacted at room temperature for 40 min. After the reaction, 1 M hydrochloric acid was added dropwise until the pH was about 2. The mixture was extracted with ethyl acetate (3×10 mL), and the organic phase was washed, dried, and purified to obtain a light yellow solid compound Boc-HBCF (93 mg, 87%). 1HNMR(300MHz,d6-DMSO)δ9.68(s,1H),7.36(d,J=8.3Hz,2H),7.14(d,J=8.4Hz,2H),7.01(d,J=8.2Hz,1H) ,6.23(d,J=2.0Hz,2H),6.14(s,1H),4.95(s,2H),4.06–3.98(m,1H),2.97–2.71(m,2H),1.32(s,9H).13C NMR(75MHz,d6-DMSO)δ174.17,158.97,155.94,153.92,139.19,137.93,132. 52,129.93,118.51,106.16,102.47,78.55,66.03,53.61,36.36,28.69.HRMS calcd for C22H26N2O8[MH]-:445.1611; found:445.1618.
[0083] Synthesis of compound HBCF:
[0084]
[0085] Compound Boc-HBCF (90 mg, 0.20 mmol) was dissolved in DCM (1 mL), trifluoroacetic acid (0.7 mL) was added, and the mixture was reacted at room temperature for 3 hours. After the reaction, the mixture was concentrated under reduced pressure to remove the excess trifluoroacetic acid, and then dissolved in water and washed with ether (5 mL) three times. The aqueous phase was frozen into a solid with liquid nitrogen, and then vacuum freeze-dried to obtain a light yellow solid compound HBCF (59 mg, 84%). 1 HNMR(300MHz,CD3OD)δ7.46(d,J=8.4Hz,2H),7.22(d,J=8.5Hz,2H),6.33(d ,J=2.0Hz,2H),6.22–6.21(m,1H),5.02(s,2H),4.21(dd,J=7.5,5.4Hz,1H), 3.30–3.04(m,2H).13CNMR(75MHz,CD3OD)δ171.27,159.74,155.85,140.25, 139.95,130.95,129.86,120.47,107.09,103.14,67.46,55.14,36.69.HRMS calcd for C17H18N2O6[MH]-:345.1087; found:345.1093.
[0086] Example 2 LC-MS analysis experiment of the reaction of HBCF and OH
[0087] After the synthesis of HBCF is completed, the present invention intends to verify its reaction with OH by liquid chromatography-mass spectrometry (LC-MS). According to the reaction mechanism ( Figure 1 ), ·OH reacts with the DHBC group of HBCF to release AF. In order to obtain a suitable retention time in the chromatographic column, a tert-butyloxycarbonyl (Boc) protected HBCF derivative, namely Boc-HBCF, was used for detection. It is expected that Boc-HBCF reacts with ·OH to generate Boc-AF ( Figure 3 ).
[0088] Boc-HBCF was reacted with 100 equivalents of ·OH at 37°C for 1 hr, followed by LC-MS analysis. Figure 4 As shown in A, the retention time of Boc-HBCF in HPLC analysis is 5.34min, while the retention time of Boc-AF in HPLC analysis is 3.69min. In the reaction solution of Boc-HBCF and ·OH, only the chromatographic peak with a retention time of 3.69min was detected in HPLC analysis, which is consistent with the retention time of Boc-AF. Mass spectrometry analysis shows that the molecular weight of the product at 3.69min after the reaction is also consistent with that of Boc-AF ( Figure 4 D, E).
[0089] This result shows that the product after the reaction has the same retention time and molecular weight as Boc-AF, that is, Boc-HBCF reacts with ·OH to generate Boc-AF. It is inferred that HBCF can react with ·OH to generate AF after site-specific insertion into proteins.
[0090] Example 3 Site-specific insertion of HBCF into proteins in E. coli
[0091] 1) Screening for synthase mutants that recognize HBCF
[0092] In order to obtain active site mutants of pyrrolysyl tRNA synthetase that can be inserted into HBCF, the present invention computationally simulates and models HBCF into the pyrrolysine binding pocket of pyrrolysyl HBCF synthetase, and notes that the side chain of HBCF may sterically conflict with many residues around the pocket (e.g., Y306, L309, C348, M350, I405, and I413V). Therefore, by rationally designing these residues to mutate to amino acids with less steric hindrance, a series of active site mutants based on wild-type pyrrolysyl tRNA synthetase were constructed. The screening experimental results of the synthetase mutants are shown in FIG. Figure 5As shown, among the 26 synthetase mutants, two (aRS and bRS) can effectively recognize HBCF and insert it into the Y39 site of EGFP, showing a strong EGFP protein fluorescence signal, while the control group without HBCF has no obvious EGFP protein fluorescence signal. This also shows that the system has good orthogonality with the natural amino acid synthetase system in E. coli.
[0093] In order to screen synthase mutants, the pLX-EGFP-Y39TAG plasmid and the constructed pBX-MmPylRS active site mutant plasmid were first co-transformed into BL21 (DE3) Escherichia coli competent cells, and the transformed monoclonal colonies were picked and shaken overnight at 37°C in LB medium containing chloramphenicol (34 μg / mL) and kanamycin (40 μg / mL). The overnight culture was diluted at a ratio of 1:100 and inoculated into fresh LB medium containing antibiotics. When the OD600 reached 0.6 at 37°C, 1 mM UAA (HBCF or BCF) was added. After 1 hour of culturing at 37°C, 1 mM IPTG was added to induce protein expression. After 9 hours of culturing at 37°C, the bacteria were collected and the fluorescence intensity of the bacterial solution was measured using a Biotek Synergy H1 microplate reader and compared with the blank control group without UAA.
[0094] Fortunately, the present invention has found a pyrrolysyl tRNA synthetase mutant that can recognize HBCF. Figure 5 , which can be effectively introduced into EGFP-Y39TAG to recognize HBCF.
[0095] 2) Experiment on the insertion efficiency of aRS and bRS into HBCF
[0096] After transferring the protein from the SDS-PAGE gel to the nitrocellulose membrane using a universal semi-dry transfer instrument (25V, 30min), it was blocked in PBST-milk solution (5% skim milk, 0.05% Tween-20) for 1hr at room temperature. The nitrocellulose membrane was then incubated with the corresponding antibody solution at 4°C overnight, washed three times with PBST (containing 0.05% Tween-20), developed with Clarity Western ECL luminescent solution, and finally imaged with ChemiDoc universal gel imager. Subsequently, the intensity of the bands in the fluorescent gel and protein blot were quantitatively analyzed using Image Lab software (Bio-Rad). .
[0097] Generally speaking, the expression level of sfGFP is higher than that of EGFP, and the insertion of UAA into the sfGFP-N150 site does not affect its fluorescence intensity. Therefore, the present invention selected sfGFP for subsequent characterization experiments. Figure 6 As shown in A, immunoblot analysis showed that under the experimental conditions, the full-length sfGFP protein containing HBCF, i.e., sfGFP-N150HBCF, can be more highly expressed under the recognition of the synthetase mutant aRS (MmPylRS-Y306A / N346A / C348A / Y384F / W417T, hereinafter referred to as HBCF-RS), so HBCF-RS was selected as the synthetase of HBCF in subsequent experiments. In addition, the present invention used the insertion of Nα-tert-butyloxycarbonyl-L-lysine (Nα-Boc-L-lysine, BocK), a well-known excellent substrate of wild-type MmPylRS, as a positive control to further confirm the insertion efficiency of HBCF. Figure 6 As shown in C, immunoblot analysis showed that under this experimental condition, sfGFP-N150HBCF was able to show an insertion efficiency comparable to that of BocK. At the same time, the concentration gradient experiment of HBCF showed that the expression level of sfGFP-N150HBCF protein increased significantly with the increase of HBCF concentration ( Figure 6 D), the protein fluorescence intensity also increased significantly ( Figure 6 E).
[0098] 3) Purified sfGFP-N150HBCF protein
[0099] The pLX-cpsfGFP-Y163TAG-Twin-Strep II plasmid was co-transformed with the pBX-HBCF-RS or pBX-BCF-RS plasmid into E. coli BL21 (DE3), and the transformed monoclonal colonies were picked and shaken overnight at 37°C in LB medium containing antibiotics. Then the overnight culture was diluted at a ratio of 1:100 and inoculated into fresh LB medium containing antibiotics. When the OD600 reached 0.6 at 37°C, 2mM HBCF or 0.5mM BCF was added. After culturing at 37°C for 1hr, 1mM IPTG was added to induce protein expression. After culturing at 37°C for 9hr, the bacteria were collected by centrifugation. When conducting protein expression analysis experiments, the collected bacteria were lysed with cell lysis buffer (50mM TEA, 150mM NaCl, 4% SDS, pH 7.4) at 95°C, then incubated with 0.2μL nuclease at room temperature for 10 minutes, and centrifuged (16,000xg, 5min) to remove cell debris. The protein concentration was determined using the BCA method. After adding 4× loading buffer and incubating at 95°C for 5min, the cell lysate can be separated on SDS-PAGE gel, and the experimental results are finally analyzed by Coomassie Brilliant Blue staining and immunoblotting. When preparing purified protein, the bacteria were ultrasonically lysed in buffer W (100mM Tris-HCl, 1mM EDTA, 150mM NaCl, pH 8.0) containing lysozyme, DNaseI, protease inhibitors and phenylmethylsulfonyl fluoride (PMSF). Then centrifuged at high speed, and the supernatant was mixed with The XT resin was incubated for 2 hours, then washed with Buffer W and eluted with Buffer BXT (Buffer W containing 50 mM biotin), and finally Buffer W was replaced with PBS buffer by dialysis. The entire process of preparing purified protein was carried out on ice or at 4°C and stored at -80°C. The antibiotic formula was 34 μg / mL chloramphenicol and 40 μg / mL kanamycin.
[0100] like Figure 7 As shown, the SDS-PAGE results showed that the band of the sfGFP-N150HBCF protein prepared and purified from E. coli was approximately 31 kDa, which was consistent with its theoretical molecular weight of 31.2 kDa ( Figure 7 A). Electrospray ionization mass spectrometry (ESI-MS) analysis showed that the protein molecular weight was 31212.03 Da, which was basically consistent with the theoretical value of 31212.76 Da ( Figure 7B). These results demonstrate that HBCF can be efficiently and highly fidelity inserted into target proteins in E. coli using the HBCF-RS / tRNAPCyUlA orthogonal pair.
[0101] The above results indicate that the unnatural amino acid HBCF can be site-specifically inserted into the target protein in Escherichia coli through genetic codon expansion technology.
[0102] Example 4 Preparation of OH fluorescent probe cpsfGFP-Y163HBCF and its in vitro OH detection
[0103] 1) Construction and preparation of OH fluorescent probe cpsfGFP-Y163PHBCF
[0104] After the successful site-specific insertion of HBCF, the present invention studies the key Tyr site of the fluorescent protein chromophore introduced by HBCF. After the insertion of HBCF at this site, it is expected that the larger side chain of HBCF will affect the fluorescence intensity of the fluorescent protein, and when it reacts with OH to remove the side chain DHBC group, the fluorescence can be restored. First, the expression levels of several commonly used green fluorescent proteins EGFP, sfGFP, cpsfGFP and red fluorescent protein mCherry inserted into UAA in Escherichia coli are compared, hoping to find the fluorescent protein with the highest expression level for subsequent in vitro reactions. Among them, EGFP, sfGFP, cpsfGFP and these green fluorescent proteins are all transformed from GFP. EGFP and sfGFP have sequences with extremely high similarity (>90%) to GFP. cpsfGFP is a circular GFP formed by connecting the N-terminus and C-terminus of sfGFP and GFP. The similarity with the GFP sequence is less than 60%. Although its primary structure amino acid sequence changes greatly, the Tyr in the chromophore still exists and has been reported for site-specific insertion of UAA. mCherry is a red fluorescent protein from mushroom coral. Although it has less than 25% sequence similarity to GFP, it still has the same properties as GFP, namely, the fluorescence signal is affected by the key site of the chromophore.
[0105] Immunoblotting analysis showed that the introduction of HBCF at the chromophore tyrosine site of several fluorescent proteins could express full-length proteins, and the expression level of cpsfGFP-Y163HBCF was the highest ( Figure 8 A). Further HBCF concentration gradient experiments showed that when the concentration of HBCF was 2mM, cpsfGFP-Y163HBCF protein could achieve a better expression effect ( Figure 8 B), therefore, a concentration of 2 mM was selected to express the cpsfGFP-Y163HBCF protein in E. coli and used as a potential ·OH fluorescent probe for subsequent in vitro detection.
[0106] The purified protein was desalted using a centrifugal filter and redissolved in ultrapure water. The protein was then analyzed by mass spectrometry using a Nano-ESI ionization source and a Q Exactive LC-MS / MS system (Thermo Scientific), and the mass spectrometry data were deconvoluted using BioPharma Finder software (Thermo Scientific). Fig. 9 As shown in the figure, SDS-PAGE results showed that the band of cpsfGFP-Y163HBCF protein prepared from E. coli was about 30 kDa and showed good purity. ESI-MS analysis showed that its protein molecular weight was 30447.41 Da, which was basically consistent with the theoretical value of 30446.81 Da. These results verified the integrity and stability of the probe for subsequent ·OH detection.
[0107] 2) ·OH fluorescent probe cpsfGFP-Y163HBCF in vitro ·OH detection
[0108] In a 96-well bottom transparent black plate, 0.5 μM cpsfGFP-Y163HBCF or cpsfGFP-Y163BCF protein was incubated with different concentrations of ·OH at room temperature for 60 min. The fluorescence spectrum of the protein in each well under 470 nm excitation or the emission fluorescence intensity at 510 nm was measured by a microplate reader. When testing the selectivity of the probe, 0.5 μM cpsfGFP-Y163HBCF protein was incubated with 5 μM ·OH or 50 μM of other possible interferents (preparation method see 2.4.4.1) at room temperature for 60 min, and then the same experimental operation was performed, and three biological replicates were performed. This experiment was carried out in 20 mM PBS buffer (pH 7.4).
[0109] The results show that if Fig.10 As shown in the figure, no matter it is the TCBQ / H2O2 system or the LH / H2O2 system, under 470nm excitation, with the increase of ·OH concentration, obvious fluorescence signal enhancement is observed at the maximum emission peak of 510nm, and both are concentration-dependent. Since the experimental steps of the TCBQ / H2O2 system are simpler, unless otherwise specified, the ·OH in subsequent experiments is generated by the TCBQ / H2O2 system ([H2O2]:[TCBQ]=10:1, [·OH]=[TCBQ]).
[0110] 3) The sensitivity and kinetic response of EcpsfGFP-Y163HBCF probe in detecting ·OH.
[0111] For further verification, the present invention statistically analyzed the fluorescence response results of the EcpsfGFP-Y163HBCF probe in the concentration range of 0-10 μM·OH. Fig.11 As shown in A, the fluorescence intensity of the cpsfGFP-Y163HBCF probe at 510nm showed a good linear correlation with the ·OH concentration between 0-4μM (R2=0.9906). Statistical analysis of the fluorescence response results of ·OH in the concentration range of 0-1μM revealed that the in vitro detection limit of the probe for ·OH was about 1μM ( Fig.11 B). In addition, kinetic analysis showed that the fluorescence on-response of cpsfGFP-Y163HBCF to ·OH reached saturation at around 60 min ( Fig.11 C).
[0112] 4) Experiment on the response of cpsfGFP-Y163HBCF probe to ·OH
[0113] Specifically, the study tested the probe's response to various potential interferents (TBCQ, H2O2) and common intracellular ROS (such as O2·-, 1O2, NO, ONOO- and HOCl, etc.), that is, cpsfGFP-Y163HBCF (0.5μM) was incubated with 50μM of the interferents at room temperature for 60min, followed by fluorescence detection. Fig.12 As shown, the cpsfGFP-Y163HBCF probe exhibits a strong fluorescence response only in the presence of ·OH and has little response to other interferents, which indicates that the cpsfGFP-Y163HBCF probe has good selectivity for ·OH.
[0114] In addition, in order to verify the response mechanism of the cpsfGFP-Y163HBCF probe to ·OH, this study used ESI-MS to analyze the protein molecular weight of cpsfGFP-Y163HBCF after ·OH treatment. Fig.13 As shown in the figure, after reacting with ·OH, the molecular weight of the protein is 30300.40Da, which is basically consistent with the theoretical molecular weight of 30300.78Da after removing the DHBC group. This result shows that cpsfGFP-Y163HBCF does react with ·OH to remove the DHBC group and generate cpsfGFP-Y163AF.
[0115] Example 5 In vitro reaction of negative control cpsfGFP-Y163BCF with ·OH
[0116] In order to further verify the mechanism of cpsfGFP-Y163HBCF probe in detecting ·OH, this study synthesized a non-natural amino acid 4-(Benzyloxycarbonylamino)-L-phenylalanine (BCF) which has a similar structure to HBCF but does not contain ·OH reactive groups. It is hoped that the cpsfGFP-Y163BCF protein will be prepared by the same method as a negative control for the cpsfGFP-Y163HBCF probe.
[0117] 1) The synthetic route of BCF is as follows Fig.14 As shown. Compound 2 obtained in Example 1 reacts with commercially available benzyl chloroformate (CbzCl) to generate compound 8. Compound 8 is sequentially deprotected with lithium hydroxide and trifluoroacetic acid to obtain unnatural amino acid BCF.
[0118] 1.1) Compound 8 Synthesis of:
[0119] Compound 2 (1.5 g, 5.10 mmol) was dissolved in DCM (50 mL), and triethylamine (1.03 g, 10.20 mmol), 4-dimethylaminopyridine (61 mg, 0.50 mmol) and benzyl chloroformate (870 mg, 5.10 mmol) were added in sequence, and the mixture was reacted at room temperature for 3 hours. After the reaction was completed, saturated ammonium chloride solution was added to quench the mixture, and then the mixture was extracted with DCM (3×15 mL). The organic phase was washed, dried, and purified to obtain a white solid compound 2-8 (1.1 g, 50%). 1 HNMR (500MHz, CDCl3) δ7.37–7.30(m,7H),7.23(s,1H),7.02(d,J=8.4Hz,2H),5.17(s,2H),5.07(d,J= 8.1Hz,1H),4.56–4.52(m,1H),3.66(s,3H),3.05–2.95(m,2H),1.41(s,9H).13CNMR(126MHz,CDCl3)δ
[0120] 172.39,155.19,153.51,137.05,136.21,130.94,129.82,128.57,128.27,128.23,118.90,79.97,66.90,54.53,52.16,37.61,28.30.HRMS calcd for C23H28N2O6[MH]-:427.1869; found:427.1875.
[0121] 1.2) Compound 9 Synthesis of:
[0122] Compound 8 (960 mg, 2.24 mmol) was dissolved in a mixed solution of 2 mL methanol and 2 mL THF, and then a solution of lithium hydroxide (109 mg, 4.48 mmol) in water (3 mL) was added and reacted at room temperature for 40 min. After the reaction, 1 M hydrochloric acid was added dropwise until the pH was about 2. The mixture was extracted with ethyl acetate (3×15 mL), and the organic phase was washed, dried, and purified to obtain a white solid compound 2-9 (848 mg, 91%). 1 H NMR (500MHz, CDCl3) δ7.34–7.32(m,7H),7.17(s,1H),7.08(d,J=8.3Hz,2H),5.17(s ,2H),5.02(d,J=7.6Hz,1H),4.60–4.59(m,1H),3.10–2.90(m,2H),1.43(s,9H).13C NMR (126MHz, CDCl3) δ176.07,155.51,153.89,137.10,136.07,131.07,130. 19,128.72,128.46,128.42,119.12,80.41,67.27,54.42,37.25,28.44.HRMS calcd forC22H26N2O6[MH]-:413.1713; found:413.1716.
[0123] 1.3) Synthesis of compound BCF:
[0124]
[0125] Compound 9 (840 mg, 2.03 mmol) was dissolved in DCM (2 mL), trifluoroacetic acid (2 mL) was added, and the mixture was reacted at room temperature for 3 hours. After the reaction, the mixture was concentrated under reduced pressure to remove the excess trifluoroacetic acid, and then dissolved in water and washed three times with ether (20 mL). The aqueous phase was frozen into a solid with liquid nitrogen, and then vacuum freeze-dried to obtain a pale white solid compound BCF (503 mg, 79%). 1H NMR(500MHz,d6-DMSO)δ9.70(s,1H),7.41–7.36(m,7H),7.15(d,J=8.3Hz,2H),5.14(s,2H),3.07(dd,J=14.3,4.2Hz,1H),2.84–2.71(m,1H).13C NMR(126MHz,d6-DMSO)δ170.60,153.92,138.77,137.15,130.34,129.13,128.93,128.52,119.34,66.23,53.80,35.74.HRMS calcd forC17H18N2O4[MH]-:313.1188; found:313.1195.
[0126] 2) Screening and identification of BCF synthase mutants
[0127] Using the same screening strategy with EGFP as a model protein, the unnatural amino acid BCF was introduced into EGFP-Y39TAG, and the insertion efficiency of the synthetase mutants was screened in E. coli. Fig.15 As shown, cRS (MmPylRS-Y306A / L309A / N346A / C348A / Y384F, named BCF-RS) was screened and BCF can be inserted into EGFP-Y39TAG to significantly increase the fluorescence signal of EGFP.
[0128] 3) BCF inserts proteins into E. coli
[0129] In order to investigate the efficiency of BCF-RS in recognizing and inserting into BCF, BCF-RS and sfGFP-N150TAG plasmid were co-transformed into BL21(DE3) competent cells of Escherichia coli. Immunoblotting analysis showed that under the experimental conditions, the full-length sfGFP protein containing BCF, namely sfGFP-N150BCF, could be expressed normally and showed an insertion efficiency comparable to that of BocK ( Fig.16 A). Further concentration gradient experiments showed that saturated expression was achieved at a BCF concentration of 0.25 mM ( Fig.16 B). cpsfGFP-Y163BCF was expressed and purified in E. coli at a concentration of 0.25 mM and used as a negative control for the cpsfGFP-Y163HBCF fluorescent probe.
[0130] The cpsfGFP-Y163BCF protein was purified and further confirmed by protein profiling. Fig.17As shown in the figure, the SDS-PAGE results showed that the band of the cpsfGFP-Y163BCF protein prepared from Escherichia coli was about 30 kDa, which was consistent with its molecular weight of 30.4 kDa. ESI-MS analysis showed that its protein molecular weight was 30414.23 Da, which was basically consistent with the theoretical value of 30414.82 Da. This verified the integrity and stability of the cpsfGFP-Y163BCF protein.
[0131] 0.5 μM cpsfGFP-Y163HBCF probe and negative control cpsfGFP-Y163BCF protein were incubated with different concentrations of ·OH at room temperature for 60 min, and then the fluorescence signal was detected. Fig.18 As shown in A, the fluorescence intensity of the probe cpsfGFP-Y163HBCF increased with the increase of ·OH concentration, while the negative control cpsfGFP-Y163BCF did not have obvious fluorescence enhancement. In addition, no fluorescence emission of the negative control probe was detected in the 490nm-600nm spectral range ( Fig.18 B). This further illustrates that the probe cpsfGFP-Y163HBCF detects ·OH through the reaction of HBCF with ·OH.
[0132] Taken together, these results indicate that the genetically encoded ·OH probe cpsfGFP-Y163HBCF can selectively detect ·OH in vitro.
[0133] In summary, the present invention successfully developed a ·OH-reactive HBCF, and the cpsfGFP-Y163HBCF genetically encoded fluorescent probe prepared based on it can be used to detect and image ·OH in solution.
[0134] The above description of the specific embodiments of the present invention does not limit the present invention. Those skilled in the art may make various changes or modifications based on the present invention. As long as they do not depart from the spirit of the present invention, they should all fall within the scope of the claims attached to the present invention.
Claims
1. An unnatural amino acid, the structural formula of which is shown below: It is characterized in that Contains 4-amino-L-phenylalanine structure.
2. The unnatural amino acid according to claim 1, characterized in that The unnatural amino acid is a genetically encoded hydroxyl radical reactive unnatural amino acid.
3. A hydroxyl radical reactive non-natural amino acid according to claim 1 or 2, characterized in that: The method for preparing the non-natural amino acid comprises the following steps: Step 1) firstly protecting the carboxylic acid group of compound 1 Nα-tert-butyloxycarbonyl-4-amino-L-phenylalanine with methyl ester to obtain compound 2; Step 2) Compound 3 3,5-dihydroxybenzoic acid methyl ester is treated with tert-butyldimethylsilyl chloride to protect the hydroxyl group to obtain compound 4; Step 3) Compound 4 is reduced with lithium aluminum hydride to obtain compound 5; Step 4) Compound 5 reacts with triphosgene and then reacts with compound 2 to generate compound 6; Step 5) After deprotection with tetrabutylammonium fluoride, lithium hydroxide and trifluoroacetic acid, a hydroxyl radical-reactive non-natural amino acid is obtained.
4. A composition comprising the unnatural amino acid of claim 1.
5. An expression system and a translation system comprising the unnatural amino acid according to claim 1.
6. Use of a reactive non-natural amino acid as claimed in claim 1 or 2 in constructing a hydroxyl radical reactive fluorescent probe.
7. The hydroxyl radical fluorescent probe of claim 6 is a fluorescent protein probe of cpsfGFP-Y163HBCF genetically encoded by introducing the non-natural amino acid of any one of claims 1-2 into a specific site of a biological macromolecule.
8. A composition comprising the hydroxyl radical-reactive fluorescent probe according to claim 6 or 7.
9. An expression system or translation system comprising the hydroxyl radical-reactive fluorescent probe according to claim 6 or 7.
Citation Information
Patent Citations
Mutant pyrrolysyl-tRNA synthetase, and method for production of protein having non-natural amino acid integrated therein by using the same
CN101952428A
Preparation for protein or peptide labeled by unnatural amino acid
CN104099360A
Novel unnatural amino acid marked antibody-drug conjugate and preparation thereof
CN106146663A
Genetically encoded formaldehyde reactive unnatural amino acid, preparation method and application thereof
CN111747869A
